Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Who Have Failed Previous Treatments-Phase II study

Phase 2

• Conditions: Patients with non-squamous non-small cell lung cancer who have failed previous treatments

• Registration Number: JPRN-UMIN000005608
• Lead Sponsor: Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine Faculty of Medicine, Tottori University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-05-23
• Study Completion: 2015-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Not provided

Exclusion Criteria

(1)Received transfusion or G-CSF within 14 days prior to enrollment (2)Urine protein>=2+ (3)History of drug allergy (4)Active multiple cancers (5)Severe infection (6)High fever (7)Abnormal cardiac function (8)Severe pulmonary disease; Interstitial pneumonia, severe COPD, pulmonary thromboembolism (9)Need for drainage of pleural effusion, acsites or pericardial effusion (10)History of hematoemesis, ileus and gastroduodenal ulcer (11)symptomatic CNS metastases (12)CNS or Psychological disorders (13)Medically uncontrolled hypertension or diabetes mellitus (14)Nonhealing wound and surgery within 4 weeks before treatment (15)History of hemoptysis; one-half teaspoon of bright red blood per event (16)Therapeutic anticoagulation(full-dose therapeutic anticoagulation current and recent use of aspirin (>=325 mg/day) (17)severe bone marrow suppression (18)Pregnancy or lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression free survival

Secondary Outcome Measures

Name	Time	Method
Safety, Disease control rate, Overall response rate, Time to treatment failure, Overall survival